Maziar Divangahi, Ph.D. Professor of Medicine Strauss Chair in Respiratory Diseases Assoc Director, Meakins-Christie Laboratories Assoc Director, ÎÛÎÛ²ÝÝ®ÊÓƵ International TB Centre Co-Leader, Program for Translational Research in Respiratory Diseases RI-MUHC, Centre for Translational Biology Ìý Research Institute of the ÎÛÎÛ²ÝÝ®ÊÓƵ University Health Centre Tel: (514) 934-1934 Ext. 76431 |
ÌýResearch
Focus
Dr. Maziar Divangahi is a Professor of Medicine at ÎÛÎÛ²ÝÝ®ÊÓƵ University. Dr. Divangahi is the
Associate Director of the Meakins-Christie Laboratories, Co-Leader of the Respiratory Program
at ÎÛÎÛ²ÝÝ®ÊÓƵ University Health Centre, and an Associate Director of the ÎÛÎÛ²ÝÝ®ÊÓƵ International TB
Centre. He is an internationally recognized pulmonary immunologist and the overarching focus of
his research program is to investigate the regulatory mechanisms involved in host resistance and
disease tolerance against major pulmonary bacterial (Mycobacterium tuberculosis) and viral
(influenza virus and SARS-CoV2) pathogens. He is currently investigating how to harness the
power of innate immunity in vaccine via reprogramming of hematopoietic stem cells. Throughout
his career, he has been a proliferative investigator publishing in outstanding journals and received
numerous awards, including a CIHR New Investigator Award, FRQS Award, and the CIHR
Foundation grant. His scholarly work has been recognized by election to the Royal Society of
Canada. He is currently holding the Strauss Chair in Respiratory Diseases.
Ìý
Keywords
Selected Publications
Kaufmann E, Khan N, Tran KA, Ulndreaj A, Pernet E, Fontes G, Lupien A, Desmeules P, McIntosh F, Abow A, Moorlag SJCFM, Debisarun P, Mossman K, Banerjee A, Karo-Atar D, Sadeghi M, Mubareka S, Vinh DC, King IL, Robbins CS, Behr MA, Netea MG, Joubert P, Divangahi M. BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell Rep. 2022 Mar 8;38(10):110502. doi: 10.1016/j.celrep.2022.110502. Epub 2022 Feb 21. PMID: 35235831; PMCID: PMC8858710.
Divangahi M, Aaby P, Khader SA, Barreiro LB, Bekkering S, Chavakis T, van Crevel R, Curtis N, DiNardo AR, Dominguez-Andres J, Duivenvoorden R, Fanucchi S, Fayad Z, Fuchs E, Hamon M, Jeffrey KL, Khan N, Joosten LAB, Kaufmann E, Latz E, Matarese G, van der Meer JWM, Mhlanga M, Moorlag SJCFM, Mulder WJM, Naik S, Novakovic B, O'Neill L, Ochando J, Ozato K, Riksen NP, Sauerwein R, Sherwood ER, Schlitzer A, Schultze JL, Sieweke MH, Benn CS, Stunnenberg H, Sun J, van de Veerdonk FL, Weis S, Williams DL, Xavier R, Netea MG. Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol. 2021 Jan;22(1):2-6. doi: 10.1038/s41590-020-00845-6. Erratum in: Nat Immunol. 2021 Jul;22(7):928. PMID: 33293712; PMCID: PMC8020292.
Khan N, Downey J, Sanz J, Kaufmann E, Blankenhaus B, Pacis A, Pernet E, Ahmed E, Cardoso S, Nijnik A, Mazer B, Sassetti C, Behr MA, Soares MP, Barreiro LB, Divangahi M. M. tuberculosis Reprograms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity. Cell. 2020 Oct 29;183(3):752-770.e22. doi: 10.1016/j.cell.2020.09.062. PMID: 33125891; PMCID: PMC7599081.
Moorlag SJCFM, Khan N, Novakovic B, Kaufmann E, Jansen T, van Crevel R, Divangahi M, Netea MG. β-Glucan Induces Protective Trained Immunity against Mycobacterium tuberculosis Infection: A Key Role for IL-1. Cell Rep. 2020 May 19;31(7):107634. doi: 10.1016/j.celrep.2020.107634. PMID: 32433977; PMCID: PMC7242907.
Khader SA, Divangahi M, Hanekom W, Hill PC, Maeurer M, Makar KW, Mayer-Barber KD, Mhlanga MM, Nemes E, Schlesinger LS, van Crevel R, Vankayalapati R(, Xavier RJ, Netea MG; Bill and Melinda Gates Foundation Collaboration for TB Vaccine Discovery Innate Immunity Working Group18. Targeting innate immunity for tuberculosis vaccination. J Clin Invest. 2019 Sep 3;129(9):3482-3491. doi: 10.1172/JCI128877. PMID: 31478909; PMCID: PMC6715374.
Tzelepis F, Blagih J, Khan N, Gillard J, Mendonca L, Roy DG, Ma EH, Joubert P, Jones RG, Divangahi M. Mitochondrial cyclophilin D regulates T cell metabolic responses and disease tolerance to tuberculosis. Sci Immunol. 2018 May 11;3(23):eaar4135. doi: 10.1126/sciimmunol.aar4135. PMID: 29752301.
Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonça LE, Pacis A, Tzelepis F, Pernet E, Dumaine A, Grenier JC, Mailhot-Léonard F, Ahmed E, Belle J, Besla R, Mazer B, King IL, Nijnik A, Robbins CS, Barreiro LB, Divangahi M. BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. Cell. 2018 Jan 11;172(1-2):176-190.e19. doi: 10.1016/j.cell.2017.12.031. PMID: 29328912.
External Links
ÌýInternational Innovation article on Maziar_Divangahi.pdf
International Innovation,Ìýpublished by Research Media, is the leading global dissemination resource for the wider scientific, technology and research communities,Ìýdedicated to disseminating the latest science, research and technological innovations onÌýa global level. More information and a complimentary subscription offer to the publication can be found at:
Ìý